Browse Articles

Discover research articles across all indexed journals

Characterization and reduction of RF loss up to 110 GHz by optimizing the UID-GaN layer in N-polar GaN material

Applied Physics Letters Yu Qi, Yu Zhou, Qian Li et al. Feb 10, 2025 DOI: 10.1063/5.0256418

In this work, the mechanism of RF loss up to 110 GHz for N-polar GaN has been studied. With the assistance of S-parameter characterization combined with secondary ion mass spectroscopy analyses, the incorporated oxygen impurity has been identified to be the main source bringing about the severe RF loss of N-polar GaN. The compensation of Fe-doping enables an effective reduction in RF loss. Moreover, the unintentionally doped (UID) GaN layer grown on top of the Fe-doped GaN buffer requires a careful design due to the distinct memory effect of Fe-doping in N-polar GaN. With an optimization of its thickness, a very low RF loss of 0.36 dB/mm at 94 GHz has been attained. Furthermore, by fitting the Fe concentration profile of UID-GaN according to the mass balance rate equation, it is found that the desorption of Fe on the N-polar GaN surface is significant. A bond-based model is introduced to elucidate the difference of the Fe memory effect between Ga-polar and N-polar GaN.

Modeling daily evapotranspiration time series based on Non-Linear Autoregressive Exogenous (NARX) method and climate variables for a data-deficient region

PLoS ONE Imee V. Necesito, Junhyeong Lee, Kyunghun Kim et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318675

For flood-prone, developing nations where hydrological data is scarce, an innovative methodological approach is essential. This study aims to explore the potentiality of modelling daily evapotranspiration time series by checking causal relationship among the available climate variables in a flood-prone, data-deficient region like Samar in the Philippines. First, to verify if the available variables (rainfall, air pressure and the four (4) Niño Sea Surface Temperature (SST) Indices) have direct effects to evapotranspiration, a causality test called Convergent Cross-Mapping (CCM) was used. Interestingly, only the Niño SST indices and air pressure were found to have direct effects. Results showed that air pressure and the four (4) Niño SST Indices when combined with Non-Linear Autoregressive Exogenous (NARX) method, can effectively model evapotranspiration. This study raises a significant advancement in evapotranspiration modelling as it is the first to model and pinpoint the potentiality of causal relationship of air pressure and the four (4) Niño SST Indices to daily evapotranspiration time series. This method is found to be potentially suitable for disaster-prone regions where hydrological data is limited.

Advancing artemisinin resistance monitoring using a high sensitivity ddPCR assay for Pfkelch13 mutation detection in Asia

Scientific Reports Suttipat Srisutham, Aungkana Saejeng, Nardlada Khantikul et al. Feb 10, 2025 DOI: 10.1038/s41598-025-86630-7

Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).

Journal of Clinical Oncology Mohammad Jad Moussa, Alexander Andreev-Drakhlin, Amishi Yogesh Shah et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.818

818 Background: MSI-high (MSI-H) and dMMR are three times more common in UTUC than bladder cancer. While these features enhance ICI sensitivity in solid tumors, data on ICIs in advanced UTUC with dMMR/MSI-H remain scarce. Methods: We retrospectively reviewed records of patients (pts) with locally advanced (LA) or metastatic with dMMR/MSI-H UTUC treated with ICIs at MD Anderson (2015-2024). Descriptive statistics and the Kaplan-Meier method were used. Results: Twenty-four pts with LA/unresectable (n=8) or metastatic (n=16) disease were treated with ICIs (pembrolizumab, n=17; nivolumab, n=4; atezolizumab, n=3) (Table). Tumor origin was the ureter (10, 41.7%) or renal pelvis (14, 58.3%). Twenty-two (91.7%) pts had Lynch syndrome, mostly (n=20) detected by germline mutation testing ( MSH2 , n=12; MLH1 , n=5; MSH6 , n=3).Twenty-one (87.5%) pts had IHC-proven dMMR(MSH2/MSH6 loss, n=7; PMS2/MLH1 loss, n=5; MLH1 loss, n=4; MSH2 loss , n=3; MSH6 loss, n=3). The most frequent alterations in somatic genetic testing for 22 pts were MSH2 (12 pts), CREBBP (7 pts), ARID1A (7 pts) and NOTCH3 (7 pts). Fourteen (58.3%) pts received prior platinum chemotherapy: cisplatin (n=9) or carboplatin-based (n=5), with only 35.7% showing responses (one complete response [CR] and 4 partial responses [PR]).With a median follow-up of 54.3 months (mo) [95% CI: 19.5 – 87.1], median PFS was 55.8 mo [95% CI: 19.4 – NE]. Milestone PFS probabilities at 12 and 24 mo were 90.7% [95% CI: 79.2% – 100%] and 69.2% [95% CI: 51.3% – 93.4%], respectively.At a median follow-up of 51.3 mo [95% CI: 34 – 60.2], median OS was not reached. Median time on treatment was 13.5 mo [IQR: 4 – 25.8]. Eight (33.3%) pts remain progression-free beyond 4 years. ORR was 79.2%, including 16 CR (66.7%) and 3 PR (12.5%), while DCR was 95.8%.Median time to best response was 11.9 mo [IQR: 5.6 – 20]. Four (16.7%) pts were offered surgical consolidation with these outcomes: ypTaN0M0, ypT0N0M0, ypT1N0M0 and mypT1N0 M1-NED. Grade ≥3 immune-mediated toxicity events leading to ICI discontinuation (n=6) included hepatitis (n=3), pancytopenia (n=1), polyendocrinopathy (n=1) and diarrhea (n=1). Conclusions: Single-agentICIs show remarkable efficacy and durable responses in advanced dMMR/MSI-H UTUC, with one-third of pts remaining in remission after over 4 years. Our findings support dMMR/MSI-H as a predictive and prognostic biomarker in UTUC and the use of single-agent ICIs in this subpopulation. Variable Measure Age at dx of advanced disease, median [ICR] 66 [55.8 – 72.3] Sex, male (n, %) 14 (58.3%) Race/Ethnicity, n (%)  White 19 (79.2%)  Black 1 (4.2%)  Hispanic 2 (8.3%)  Asian 2 (8.3%) Urothelial carcinoma mixed with variant histology, n (%) 3 (12.5%) Liver mets at ICI start, n (%) 2 (8.3%) Bone mets at ICI start, n (%) 5 (20.8%) Hemoglobin <10 g/dL at ICI start, n (%) 5 (20.8%) Bellmunt score, n (%)  0-1 19 (79.2%)  2 3 (12.5%)  3 2 (8.3%)

Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a targeted literature review (TLR).

Journal of Clinical Oncology Mairead Kearney, Rosanne Janssens, Matt Quaife et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.755

755 Background: The treatment landscape for la/mUC has evolved with multiple care options available. As new therapies are adopted, decision-making among physicians, patients, and their caregivers becomes more complex and challenging. This study summarizes the existing literature on preferences of patients and caregivers about aspects of treatment following a diagnosis of la/mUC. Methods: A TLR of English-language conference abstracts and full-text manuscripts published from 2015 was conducted using Embase and PubMed, to identify qualitative and quantitative studies on the treatment preferences of patients with la/mUC and caregivers of people with la/mUC. Literature was independently screened against predefined eligibility criteria by two researchers, with a third researcher resolving disagreements. Results: Data from 13 publications were extracted (n=10 [77%] qualitative, n=3 [23%] quantitative); of these, 6 (46%) were full-text manuscripts and 7 (54%) were conference abstracts/posters. When specified, most studies (6/10 [60%]) were conducted in the US. Six studies (46%) assessed preferences among both patients and caregivers. The quantitative preference studies assessed varied efficacy endpoints, including overall survival (n=2), overall response rate (ORR; n=1), and progression-free survival (n=1). Treatment efficacy was the most important consideration in 2 quantitative studies, while 1 study found adverse events (AEs), combined with number and duration of medicines, to be more important to patients. Across publications, attributes related to treatment AEs significantly impacted preferences. Unmet needs related to symptoms and AEs were identified. The symptoms/AEs reported most frequently across all 13 studies were fatigue (n=7 [53%]), cancer-related pain (n=6 [46%]), peripheral neuropathy (PN; n=3 [23%]), blood in urine (n=3 [23%]), and nausea (n=3 [23%]). In 1 quantitative study, cancer-related pain was ranked as the second most important treatment attribute after ORR. Patients in this study also indicated that they would accept a 7.8% reduction in ORR to reduce the risk of developing PN by 10%. Of 3 studies that compared differences between patient and caregiver preferences, 2 quantitative studies found that caregivers placed a higher importance on avoiding side effects than patients. Conclusions: Despite heterogeneity in study designs and outcomes reported, patients and caregivers often prioritized treatment efficacy over tolerability. However, in quantitative studies, patients and caregivers were willing to accept lower efficacy for a more tolerable treatment, although the magnitude of trade-offs varied by AE. Such insights highlight the importance of incorporating patient and caregiver preferences in shared decision-making and personalizing treatment according to individual patient goals.

Impact of concomitant medication use on treatment outcomes in patients with RCC treated with immune checkpoint inhibitors.

Journal of Clinical Oncology Ahmet Yildirim, Mengting Wei, Yuan Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.603

603 Background: Multiple studies on various cancer types have investigated concomitant statin, aspirin, and metformin use with immune checkpoint inhibitors. While some found improved OS and PFS, others reported no significant effect. In RCC, a retrospective study linked statins with improved OS and PFS. We aimed to evaluate the impact of statin, aspirin, and metformin use on survival in RCC patients treated with ICIs. Methods: A retrospective analysis was conducted on adult patients with advanced RCC treated with ICIs at Emory Winship Cancer Institute between 2018 and 2024. Concomitant medication use was assessed via chart review during active ICI treatment. Clinical benefit (CB) is determined by stable disease, partial response, and complete response. The multivariate analysis model for statin was built by controlling the age, gender, race, smoking status, IMDC risk group, ECOG PS, clear cell histology, prior treatments, and liver metastases. Variables were subject to backward elimination at the significant level of p < 0.2. Results: Data from 400 patients were analyzed, with a median follow-up of 43.0 months (95% CI: 36.6-51.4). Of 400 patients, 138 (34.5%) were treated with ICI monotherapy, 131 (32.8%) treated with dual ICI combination, and 114 (28.5%) were treated with ICI and TKI combinations. 85 (21.3%) of the patients were African American or Black, 284 (71%) of them were White, and 239 (59.8%) were treated with ICIs as first-line. Statin use was more common among patients without prior treatment, without liver metastasis, older individuals, and those with a BMI ≥24.9. In univariate analysis, statin use showed potential associations with longer OS (HR 0.82; 95% CI 0.62-1.07 p=0.144), longer PFS (HR 0.81; 95% CI 0.64-1.02 p=0.071), and a higher likelihood of receiving CB (OR 1.85; 95% CI 1.17-2.92 p=0.008). However, multivariate analysis did not confirm significant differences in survival or CB. Survival outcomes are summarized in the table. Conclusions: Our analysis found no significant impact of concomitant statin, aspirin, or metformin use on RCC patient outcomes treated with ICIs. Further advancements in our understanding of tumor biology and checkpoint inhibitors might explain how concomitant medication affects treatment outcomes. Our study is limited by its retrospective design, and future prospective trials are necessary to provide definitive evidence. Univariate analysis of survival outcomes and clinical benefit. Overall Survival Progression-free survival Clinical Benefit HR (95% CI) p-value HR (95% CI) p-value OR (95% CI) p-value Statin Y n=170 0.82 (0.62-1.07) 0.144 0.81 (0.64-1.02) 0.071 1.85 (1.17-2.92) 0.008 Statin N n=230 - - - - - - Aspirin Y n=138 0.93 (0.70-1.24) 0.623 0.84 (0.66-1.07) 0.159 1.49 (0.93-2.40) 0.100 Aspirin N n=262 - - - - - - Metformin Y n=49 1.04 (0.68-1.57) 0.860 0.80 (0.55-1.15) 0.231 1.37 (0.68-2.78) 0.379 Metformin N n=351 - - - - -

Rates of first next-generation sequencing (NGS) testing at the end of life in patients (pts) with advanced urothelial carcinoma (aUC).

Journal of Clinical Oncology Chadi Hage Chehade, Yeonjung Jo, Zeynep Irem Ozay et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.727

727 Background: Despite the availability of targeted therapies like erdafitinib for pts with aUC with susceptible genomic alterations, the rate of NGS testing remains low at 32% in the United States (Hage Chehade...Swami, JAMA Network Open, 2024). Furthermore, limited data exist regarding the timing of NGS testing in relation to the time of death. Herein, we sought to assess the rates of NGS testing at the end of life in pts with aUC in a real-world patient population. Methods: A de-identified nationwide Flatiron Health electronic health record (EHR)-derived database was used to extract patient-level data. Inclusion criteria: pts who received NGS testing (blood/tissue) and who had a date of death recorded. The analytic cohort included pts diagnosed with aUC between 1/1/2011 and 11/14/2022 who received first NGS testing results between 5/3/2012 and 12/21/2022. The time difference between each pt’s first NGS result delivered and death was calculated, and thereafter, pts were categorized into 3 categories: pts receiving results > 3 months (mo) before death, within 3 mo of death, or after death. The frequency and percentages of the 3 categories were reported, as well as by year of death. The percentages in each category were compared between 2019 (year of erdafitinib approval) and 2022 (last year in dataset) to evaluate changes in NGS testing trend. Results: Among 12,157 pts with aUC in the dataset, 1,637 had both a recorded date of death and underwent NGS testing, and were eligible and included in final analysis. The median age was 72 (IQR 66 – 79). The majority were male (73%), White non-Hispanic (76%), and treated in community practice (86%). 68.2% received NGS results > 3 mo before death (n = 1,117), 28.3% received results within 3 mo of death (n = 464), and 3.4% of NGS results were reported after death (n = 56). In pts who died in 2019 versus 2022, the percentage of pts receiving NGS results > 3 mo before death increased from 61% to 75%, while the percentage of pts receiving results within 3 months decreased from 33% to 22%, and the percentage of NGS results reported after death declined from 5.2 to 2.7%. Baseline characteristics (including race-ethnicity, insurance plan, practice type [academic vs. community]) in these categories will be presented at the meeting. Conclusions: Our findings suggest that a sizeable number of pts with aUC (∼ 32%) received their first NGS testing results towards the end of life, highlighting the need to integrate genomic testing earlier during the course of the disease to optimize benefit with targeted therapies. These results could inform clinical practice and therapeutic decisions in the clinic. CHC, YJ: Equal contribution; US, NA: Senior authors.

Spin wave propagation in YIG waveguides with magnetic microvolcanoes: Experiment and simulation

Applied Physics Letters A. B. Khutieva, A. V. Sadovnikov, F. E. Garanin et al. Feb 10, 2025 DOI: 10.1063/5.0241539

Control of spin wave transport in polymer 3D films was realized by magnetic microvolcanoes embedded in waveguides, fabricated by soft-matter specific techniques. Propagate of the spin wave signal excited in yttrium iron garnet (YIG) with 3D self-standing microvolcanoes chambers on top filled by the magnetic nanoparticles was evaluated by Brillouin light scattering and microwave spectroscopy. The magnetic moment of the polymer microvolcanoes varied with the change of the magnetic field bias direction inside the YIG films, which was shown by 2D mapping of the outer surface of the films. The good correlation of micromagnetic modeling and experimental data of spin wave propagation in the multistructure as a function of the applied magnetic field was clarified by the convergence parameters of the obtained polymer 3D magnetic microvolcanoes fields and the standard theory of spin wave propagation. The uniqueness of the soft materials object—polymer magnetic 3D films on conductive YIG film—lies in the application of the magnon network properties, which may find application in biomedical high-sensitivity feedback sensors.

PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes

PLoS ONE Sophie St-Amour, Laurence Tessier, Janie Harnois et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0305511

Type 2 diabetes (T2D) is a chronic disorder affecting 462 million worldwide, often managed with metformin as first-line treatment. However, metformin’s response varies among individuals, including up to 30% experiencing serious adverse drug reactions (ADRs) and 20-50% inefficacy. These differences may be due to various factors, including pharmacogenetic (PGx) variants. The PGx variants documented so far could affect both the safety and efficacy of metformin, but due to a lack of replication studies, none reached the clinical evidence-level needed to be used as a predictive marker for treatment response. Therefore, this study aims to evaluate the association between the presence of candidate PGx variants and metformin response in T2D subjects. We conducted an association study involving 108 T2D participants currently or previously treated with metformin. A characterization of their therapeutic response was carried out through questionnaires and pharmacological profile reviews. DNA samples were collected during their single visit to perform genotyping of 24 selected candidate PGx variants. Association analyses between candidate PGx variants and metformin response were performed. Among the subjects included in the analyses (n =  84), 25% were non-responders, and 58% experienced ADRs. At the time of study enrollment, 93.9% of non-responders continued to use metformin. The odds of being a non-responder to metformin are 5.6 times higher for homozygous carriers of the alternative allele of a variant within the PCK1 gene (rs4810083) compared to the other genotypes (95% interval confidence [1.9–16.6]). Two variants in perfect linkage disequilibrium within the SLC22A2 gene (rs316019 and rs316009) were associated with increase odds of having ADRs, where homozygous genotype carriers are 7.3 times more likely to have ADRs presentation (95% interval confidence [1.85–29.01]). This study identified associations between PCK1 and SLC22A2 candidate PGx variants and metformin response in T2D treatment. Additional genetic and functional studies are necessary to elucidate the variants’ impact in metformin’s pharmacological mechanisms.

Assessment of the environmental impacts of regional groundwater flow path fluctuations in the water-stressed drought prone Northern Region of Bangladesh

Scientific Reports Md. Moniruzzaman Monir, Subaran Chandra Sarker, Rathindra Nath Biswas et al. Feb 10, 2025 DOI: 10.1038/s41598-024-77617-x

A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.

Journal of Clinical Oncology David Levitz, Martin Gutierrez, Ira Seth Winer et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps652

TPS652 Background: Claudin-6 (CLDN6) is overexpressed in solid tumors including germ cell tumors (GCTs) with minimal expression in healthy tissue. This differential expression profile makes CLDN6 a suitable tumor-associated antigen for a T-cell engaging bispecific antibody (bsAb). XmAb541 is a first-in-class humanized, anti-CLDN6 x anti-CD3 bsAb that directs T-cell cytotoxicity. The XmAb 2+1 format provides avid tumor targeting and selectivity. Importantly, XmAb541 selectively binds CLDN6, with reduced binding to other claudin family proteins (e.g., CLDN9) and non-CLDN6-expressing healthy tissue [1]. This study focuses on subjects with GCT and other CLDN6+ solid tumors who have failed standard therapy and have a high unmet medical need. The primary objective of the trial is to determine an optimal and tolerated dose(s) for further evaluation. Methods: This is a first-in-human, Phase 1, open-label study to evaluate the safety and tolerability of XmAb541 in advanced solid tumors. The study will be conducted in 2 Parts. Part 1, Dose Escalation, will establish a dosing regimen inclusive of a priming dose, step-up dose(s), and the target dose. Part 2 Dose Expansion will further evaluate safety and tolerability and provide an initial evaluation of preliminary antitumor activity for the dose regimen(s) established in Part 1. XmAb541 will be administered intravenously. Key inclusion criteria are age ≥ 18 years (for subjects with GCTs, age ≥15 years). Have histological evidence of locally advanced, recurrent, or metastatic GCT, ovarian, fallopian tube, peritoneal cancer, or adenocarcinoma of the endometrium. Have documented progressive disease on standard-of-care therapies; exhausted therapies with a survival benefit, or the standard therapy has no survival benefit or proven to be ineffective, intolerable, or subject is not a candidate for such available therapy. Subjects must have an Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy ≥ 3 months with adequate liver, kidney, and bone marrow function. Key exclusion criteria include the following: known active central nervous system metastases and/or carcinomatous meningitis. Subjects with treated brain metastases may participate, provided they are radiologically stable. Ethics approval: This study was approved by WCG IRB. References: 1. Faber, M. Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells. (AACR 2021, Abstract No. 1860). Clinical trial information: NCT06276491 .

Real-world effectiveness and safety of first-line (1L) avelumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.

Journal of Clinical Oncology Axel Stuart Merseburger, Olga Baklanova, Victor T. Garlonta et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.474

474 Background: In the JAVELIN Renal 101 phase 3 trial, 1L avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) vs sunitinib in patients with aRCC, with an acceptable safety profile. The AVION study is evaluating the effectiveness and safety of avelumab + axitinib in routine clinical practice in various countries. We report data from the primary analysis. Methods: AVION is a prospective noninterventional study of patients with aRCC receiving 1L avelumab + axitinib in Germany, Greece, Belgium, or Russia. Patients are observed for 24 months. The primary objective is to evaluate the overall survival (OS) rate at 12 months. Secondary objectives include evaluation of OS rate at 24 months, median OS, PFS, ORR, duration of response (DOR), and safety. Results: By data cutoff (Jul 5, 2024), 104 patients were analyzed. Median age was 70 years (range, 37-87) and 70.2% were male. ECOG PS was 0-1 in 92.3%, 2 in 6.7%, and not reported (NR) in 1.0%. International Metastatic RCC Database Consortium (IMDC) risk group was favorable, intermediate, poor, and NR in 26.0%, 45.2%, 12.5%, and 16.3%, respectively. Tumor histology was clear cell, sarcomatoid, and other in 89.4%, 3.8%, and 6.7%, respectively. Prior anticancer treatment included adjuvant drug treatment, surgery (nephrectomy), or radiotherapy in 3.8%, 75.0% (66.3%), and 8.7%, respectively. At data cutoff, avelumab or axitinib treatment was ongoing in 21 (20.0%). Median OS was not reached (95% CI, not estimable [NE]) and the 12-month OS rate was 82.7% (95% CI, 73.5-88.9). Median PFS (95% CI) was 11.3 months (8.1-NE) and 6- and 12-month PFS rates (95% CI) were 72.5% (62.1-80.5) and 48.4% (37.5-58.5), respectively. Among 87 patients with available response data (assessed up to 12 months), ORR was 46.0% (95% CI, 35.2-57.0), comprising complete or partial response in 4.6% and 41.4%, respectively; disease control rate was 79.3% (95% CI, 69.3-87.3); and median DOR was not reached. Treatment-related adverse events (TRAEs) occurred in 67.3% and were grade ≥3 or serious in 20.2% and 14.4%, respectively. TRAEs led to permanent discontinuation of avelumab or axitinib in 6.7% or 9.6%, respectively, and led to death in 1.0%. The most common TRAEs of any grade (≥6%) were diarrhea (19.2%), fatigue (13.5%), hypothyroidism (8.7%), and nausea (7.7%). Follow-up is ongoing. Conclusions: Results from the AVION study are generally consistent with JAVELIN Renal 101 and previous observational studies, demonstrating the effectiveness, safety, and favorable tolerability with low discontinuation rates of avelumab + axitinib in a heterogeneous real-world population.

Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).

Journal of Clinical Oncology Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.17

17 Background: Interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival (PFS) and depth of PSA-response with the addition of [ 177 Lu]Lu-PSMA-617 (LuPSMA) to enzalutamide (enza) as first-line treatment of poor-risk, metastatic, castration-resistant prostate cancer (mCRPC). Here we report effects on overall survival (OS) and health-related quality of life (HRQL) with longer follow-up. Methods: We randomly assigned 162 participants (pts) to enza 160 mg daily alone, or in combination with (2 or 4 doses) LuPSMA 7.5 GBq. Eligible pts had mCRPC not previously treated with chemotherapy or an androgen receptor pathway inhibitor for mCRPC, 68 Ga-PSMA PET-avid disease, and at least 2 risk factors for early disease progression on enza-alone. HRQL was to be rated with the EORTC core quality-of-life questionnaire every 6 weeks until radiological progression. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in physical function, or in overall health and quality of life (OHQL). HRQL scores were analyzed with repeated measures modelling to calculate group means and differences. HRQL scores range from 0 (lowest possible) to 100 (highest possible). Time to event data were analysed with the Kaplan-Meier method, stratified log rank test, and stratified Cox-proportional hazards regression. Analyses of these secondary endpoints were specified a priori and are by intention to treat. P-values and confidence intervals are 2-sided without adjustment for multiple comparisons. Results: A total of 96 deaths were reported after a median follow-up of 34 months (IQR 29-39): 53 among those assigned enza-alone and 43 among those assigned enza+LuPSMA. OS was longer in the enza +LuPSMA group than the enza-alone group (median months 34 vs 26; HR 0.55, 95% CI 0.36 to 0.84; p=0.005). 30 of 79(38%) in the enza-alone arm received subsequent LuPSMA off trial. HRQL was rated by 154 of 162 pts (95%). Deterioration-free survival rates at 12 months, and stratified log-rank p-values favored enza+LuPSMA for both OHQL (40% v 13%; p &lt;0.001), and for physical function (38% v 17%; p &lt;0.001). Mean scores for pain until progression favoured the enza+LuPSMA group over the enza-alone group (difference 7.2, 95% CI 1.6 to 13; p=0.01). Mean scores for fatigue until progression favoured the enza+LuPSMA group over the enza-alone group (difference 5.9, 95% CI 1.1 to 10.7; p=0.02). The frequency of self-rated xerostomia was lower in the enza-alone group (74% vs. 57%; p=0.04). Conclusions: The addition of LuPSMA to enzalutamide in poor risk mCRPC improved overall survival, scores for both pain and fatigue, and deterioration-free survival for both physical function and for OHQL. Clinical trial information: NCT04419402 .

Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of <sup>177</sup> Lu-PSMA-617.

Journal of Clinical Oncology Johann S. de Bono, Michael J. Morris, Alton Oliver Sartor et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.16

16 Background: In PSMAfore (NCT04689828), [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) prolonged rPFS versus androgen receptor pathway inhibitor (ARPI) change in taxane-naive adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) progressing once on an ARPI. Baseline circulating tumor DNA (ctDNA) fraction was associated with rPFS at the second interim analysis (IA) of OS (ASCO 24). Here, we assessed the association of baseline and cycle 2 day 1 (C2D1) ctDNA fraction, and early ctDNA and prostate-specific antigen (PSA) dynamics, with rPFS and OS at the third IA of OS. Methods: Patients were randomized 1:1 to 177 Lu-PSMA-617 (7.4 GBq Q6W; x6) or ARPI change. Endpoints included rPFS (primary) and OS (key secondary). Plasma ctDNA fraction was analyzed at baseline and at C2D1 using an in-house custom panel. Cox regression (adjusted for 3 risk classes based on clustering of 17 baseline clinical features) and random forest (adjusted for 15 baseline clinical features) modeling were used to assess the association of ctDNA fraction and PSA with clinical outcomes at the Feb-27-2024 data cutoff. Results: Patients with plasma samples at baseline and C2D1 were included ( 177 Lu-PSMA-617, n/N = 82/234; ARPI change, n/N = 91/234). Cox regression models adjusted for clinical features in the 177 Lu-PSMA-617 arm showed that higher ctDNA fraction was associated with shorter rPFS and OS (Table). These associations were stronger for C2D1 than baseline, both when comparing individual models and within a model including both timepoints (Table). In random forest models including clinical features and C2D1 ctDNA fraction, the total area under curves were not improved by addition of baseline ctDNA fraction (rPFS, 0.87; OS, 0.86). In the overall population, fractional decreases from baseline to C2D1 in ctDNA ( p = 0.0015) and PSA ( p &lt; 0.0001) were strongly associated with longer rPFS, and were weakly correlated with one another (correlation coefficient, 0.26). In the 177 Lu-PSMA-617 arm, fractional decrease in ctDNA ( p = 0.002) was more strongly correlated with OS than was decrease in PSA ( p = 0.12). Conclusions: This exploratory analysis suggested that C2D1 ctDNA fraction was more strongly associated than baseline ctDNA fraction with rPFS and OS. Early ctDNA fraction dynamics contributed additional information in the prediction of rPFS and OS beyond PSA dynamics alone. Clinical trial information: NCT04689828 . Cox regression models. a rPFS OS Baseline model, HR (95% CI); p 6.0 (1.6–23.0); 0.0095 12.0 (3.0–48.7); 0.00052 C-index ± SE 0.69 ± 0.04 0.75 ± 0.04 C2D1 model, HR (95% CI); p 47.7 (10.1–226.0); &lt; 0.0001 82.7 (16.4–417.0); &lt; 0.0001 C-index ± SE 0.72 ± 0.03 0.77 ± 0.03 Baseline + C2D1 model Baseline, HR (95% CI); p 3.1 (0.7–14.0); 0.14 2.1 (0.4–12.7); 0.41 C2D1, HR (95% CI); p 35.9 (7.2–180.0); &lt; 0.0001 52.5 (7.6–362.0); &lt; 0.0001 C-index ± SE 0.72 ± 0.03 0.79 ± 0.03 a HRs correspond to 1 unit change in ctDNA fraction.

Topographically selective atomic layer deposition within trenches enabled by an amorphous carbon inhibition layer

Applied Physics Letters Thijs Janssen, Lodewijk J. P. Vossen, Marcel A. Verheijen et al. Feb 10, 2025 DOI: 10.1063/5.0246311

To meet the demands for more advanced computer chips, creating devices with advanced 3D architectures is becoming commonplace in the semiconductor industry. To ensure alignment between the different layers, the bottom-up technique of area-selective deposition (ASD) is promising. However, ASD may not always be feasible depending on the various surface chemistries present during manufacturing of complex semiconductor devices. Topographically selective deposition (TSD) is emerging as an alternative, focusing on differences in surface orientation rather than chemical properties. This work demonstrates a TSD supercycle approach in which atomic layer deposition (ALD) is directed to proceed exclusively within a 3D trench structure, by covering the top of the trench with an amorphous carbon (aC) inhibition layer. The aC layer is applied selectively on the top surface of the trench by exploiting the ion-radical synergy required for its deposition. Since the aC layer lacks adsorption sites for ALD precursors, growth of the target material is inhibited on the top surface of the trench, whereas it occurs selectively within the trench. After several ALD cycles of selective deposition of the target material, the aC layer is removed and reapplied in a supercycle recipe until sufficient material has been deposited in the trench. The selective deposition of an aC inhibition layer on the top surface of the trench, as well as the selective deposition of 3.0 ± 0.1 nm of TiO2 in a trench is demonstrated on a 3D nanostructure.

Effect of dietary anthocyanins on the risk factors related to metabolic syndrome: A systematic review and meta-analysis

PLoS ONE Junyin Pan, Jingwen Liang, Zhantu Xue et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0315504

Objective This meta-analysis aims to systematically investigate whether dietary anthocyanin supplementation can reduce metabolic syndrome (MetS)-related risk factors: abdominal obesity, dyslipidemia (low high-density lipoprotein cholesterol (HDL-C) and hypertriglyceridemia), hypertension, and hyperglycemia by conducting a meta-analysis of randomized controlled trials (RCTs). Methods A systematic search of 5 electronic databases (PubMed, Web of Science, Scopus, Cochrane Library, and Embase) was conducted from inception until April 25, 2024. A total of 1213 studies were identified, of which randomized controlled trials involving subjects with MetS-related factors, comparing dietary anthocyanin supplementation with placebo, and reporting results on anthropometric, physiological, and metabolic markers relevant to this study were selected. Depending on the heterogeneity of the included studies, a fixed-effect model was applied for low heterogeneity (I2 &lt; 50%), whereas a random-effects model was employed when substantial heterogeneity was present (I2 ≥ 50%). The weighted mean difference (WMD) and 95% confidence intervals (CI) were calculated. Results This meta-analysis included 29 randomized controlled trials with 2006 participants. The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers: HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). Weight: (WMD: -0.12 kg, 95% CI: -0.45 to 0.21, p = 0.473), Body mass index (BMI): (WMD: -0.12 kg/m2, 95% CI: -0.26 to 0.03, p = 0.12), Overall WC: (WMD: 0.18 cm, 95% CI: -0.51 to 0.87, p = 0.613), Systolic blood pressure (SBP): (WMD: -0.12 mmHg, 95% CI: -1.06 to 0.82, p = 0.801), Diastolic blood pressure (DBP): (WMD: 0.61 mmHg, 95% CI: -0.03 to 1.25, p = 0.061), Insulin levels: (WMD: -0.02 mU/L, 95% CI: -0.44 to 0.40, p = 0.932), HOMA-IR: (WMD: -0.11, 95% CI: -0.51 to 0.28, p = 0.573). Additionally, a 100 mg/day dosage of anthocyanins significantly reduced: Waist circumference (WC): by 0.55 cm (95% CI: -1.09 to -0.01, p = 0.047). Subgroup analyses based on intervention duration, anthocyanin dosage, health status, formulation, dosage frequency, physical activity levels, and baseline levels of corresponding markers revealed varying significances, particularly in relation to blood pressure. Conclusion Dietary anthocyanins effectively improve low HDL cholesterol, hypertriglyceridemia, and hyperglycemia, making them a promising adjunct for managing MetS. However, it is important to note that dietary anthocyanin interventions may raise systolic blood pressure (SBP) and diastolic blood pressure (DBP) depending on intervention dose, duration, participant health status, and formulation. Clinicians should fully consider these effects when recommending anthocyanin supplementation. Further long-term, well-designed, large-scale clinical trials are needed to draw definitive conclusions.

One lung ventilation during thoracoscopic lobectomy alters lung microbiome miversity and composition

Scientific Reports Zhang Ruijiao, Li Tianyuan, Wu Shiyin et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89233-4

The role of salvage cystectomy after prior trimodality therapy.

Journal of Clinical Oncology Nikolaos Pyrgidis, Gerald Bastian Schulz, Pietro Schilipoti et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.781

781 Background: Trimodality therapy (TMT) with transurethral resection followed by radiation of the urinary bladder and chemotherapy is associated with similar long-term survival rates compared to radical cystectomy (RC) for well-selected patients. Nevertheless, salvage RC may become necessary in 10% of patients receiving TMT. We aimed to assess the perioperative and long-term outcomes of salvage RC after prior TMT through a large multinational cohort study. Methods: We included patients with pure urothelial cancer of the urinary bladder. Patients undergoing salvage RC after prior TMT due to recurrence in the urinary bladder from 11 high-volume centers were matched with a propensity score matching on a 1:1 ratio with patients without prior TMT undergoing primary RC. The two groups were adjusted for institution, age, histological status, ASA score, and surgical technique. Results: We included 108 patients (54 per group) with a median age of 74 years (IQR: 66-78). The two groups did not differ in terms of operative time (TMT: 250 versus non-TMT: 251 minutes, p = 0.9), intraoperative blood loss (TMT: 550ml versus non-TMT: 600ml, p = 0.2), and perioperative Clavien-Dindo complications (p = 0.9). At a follow-up of 16 months (IQR: 6-38), 45 (42%) deaths occurred. Prior TMT was associated with higher mortality rates in the survival analysis (log-rank test: p = 0.037). Accordingly, the progression rates were higher in patients with prior TMT (log-rank test: p = 0.047). Conclusions: Salvage RC after TMT is associated with similar perioperative outcomes compared to primary RC. Nevertheless, patients undergoing salvage RC after TMT may present worse progression rates and overall survival in the long term. Therefore, systemic therapies should be considered in patients with recurrence after TMT.

Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.

Journal of Clinical Oncology Axel Heidenreich, David Pfister, Pia Paffenholz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.639

639 Background: Surgical resection of post-chemotherapy residual masses for metastatic seminoma is discussed controversially with regard to oncological and functional outcome. Furthermore, the role of FDG-PET/CT to detect vital seminoma is still unclear. It is the aim of this study is to report the outcomes of patients with pure seminoma who underwent PC-RPLND. Methods: In this retrospective international, multi-institutional study, pure seminoma patients whounderwent PC-RPLND for marker negative, FDG-PET/CT positive residual masses &gt; 3cm or a marker negative retroperitoneal relapse following first line chemotherapy between 2000 and 2023 were included. Patients with residual masses with stable disease, negative FDG-PET/CT findings, inadequate systemic chemotherapy, insufficient clinical data, positive markers, or with residual or relapsing masses following salvage chemotherapy were excluded. Perioperative and long-term outcomes of the patients were reviewed. Results: A total of 142 patients with a median (IQR) age of 39 (31 – 68) years were included. All patients received first-line cisplatin-based chemotherapy. 93% of PC-RPLNDs were performed via an open transperitoneal approach, and 7% underwent robotic surgery. 86 (61%) and 56 (39%) patients underwent a unilateral and a full bilateral resection, respectively. A nerve sparing procedure was performed in 29 (20%). Adjunctive surgery was performed in 53 (37%) patients, the most common of which were ureteral resection/repair in 19 (13%) pts, and vascular resection/repair 18 (13%) pts followed by nephrectomy in 12 (8.4%). Median (IQR) blood loss and length of hospital stay were 550 (300 – 5800) mL and 4 (2 – 18) days, respectively. Clavien - Dindo complications ≥ 3a developed in 16 (11.3%). Final pathology revealed necrosis/fibrosis in 98 (64%) and seminoma in 44 (36%). FDG-PET/CT for residual masses &gt; 3cm was performed in 56 patients with a positive predictive value of only 23%. On multivariate analysis (MVA) IGCCCG good risk (OR: 5.86, 95% CI 1.9-18.09, p&lt;0.001), solitary metastases (OR 4.77, 95% CI 1.29-17.68, p=0.017) and RPLND for non-relapsing seminoma (OR 0.1, 95% CI 0.02-0,21, p&lt; 0.001) were associated with necrosis. Adjunctive surgery (OR 4.56, 95% CI 0.39-53.5, p=0.04), and FDG-PET/CT SUV &gt; liver (OR 31, 95% CI 2.54 – 45.6, p=0.004) and marker negative progression (OR 19, 95% CI 5.6 – 31.2, p&lt;0.001) correlated with the presence of viable seminoma. With a median (IQR) follow-up of 65 (3 – 175) months, 20 (14%) patients relapsed (9/44 seminoma, 10/98 necrosis). 3 (3%) patients died of disease. Conclusions: One third of patients with progressive or &gt; 3cm FDG-PET-CT positive residual retroperitoneal masses following first-line chemotherapy for metastatic seminoma may have viable tumor. 80% of patients with viable seminoma can be cured by surgery alone.In selected cases, PC-RPLND may be a valuable option if performed in high-volume centers with expertise in testicular cancer management.

Optimizing treatment approaches in nested bladder tumors: A multicenter retrospective study.

Journal of Clinical Oncology Patrizia Giannatempo, Paolo Ambrosini, Marco Maruzzo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.743

743 Background: Identifying optimal treatment strategies in nested bladder tumors is critical. This multicenter study aims at evaluating progression-free survival (PFS) end overall survival (OS) according to disease extent, presentation and treatment including Bacillus Calmette-Guérin (BCG), radical cystectomy (RC) and chemotherapy (CT). Methods: Data were collected from 61 patients with nested bladder tumors across 5 centers over a 10-year period (2013–2023). Patients were stratified according to 1) time of diagnosis of nested variant (disease onset Vs recurrence) 2) disease extent (NMIBC vs MIB, vs cN+ Vs M+) 3) treatment groups based on their initial treatment: ( BCG ± RC vs RC only Vs RC + CT). Kaplan-Meier analysis was used to assess median PFS (mPFS) and median OS (mOS), while p-values &lt;0.05 was used to determine statistical significance across groups. Results: The median follow-up was 30.6 months (95% CI: 16.4–40.6). At diagnosis 15 (24.6%) were NMIBC, 26 (42.6%) MIBC, 15 (24.6%) N+ and 5 (8.2%) metastatic (M). Of the 15 NMIBC 80% received initial BCG. Pts with nested bladder tumors at onset had worse PFS and OS (mPFS of 99.6 months (95% CI: 55.2-NR) and mOS of 107.3 months (95% CI: 71.6-NR) than those with nested bladder tumor at recurrence mPFS of NR (95% CI: 42.1-NR) and mOS 138.4 (95% CI: 51.7-NR). None of these differences were statistically significant. Patients with M and N+ stages showed a trend towards a worse prognosis than those with NMIBC and MIBC, with no statistically difference in mPFS and mOS between MIBC and NMIBC stages. According to treatment, the best mPFS and mOS were recorded among patients receiving RC and CT [mPFS 99.6 months (95% CI: 55.2-NR) and mOS of 107.3 months (95% CI: 107.3-NR)]. Those receiving BCG followed by RC group had a mPFS of 84.2 months (95% CI: 68.1-NR) and mOS of 85.9 months (95% CI: 71.6-NR) while those undergoing RC alone apparently had the worse mPFS of 42.1 months (95% CI: 42.1-NR) and mOS of 51.7 months (95% CI: 14.7.1-NR). None of these differences were statistically significant. Conclusions: This study represents the largest case series of nested bladder tumors. It suggests limited benefit from BCG treatment. Most patients had advance disease, most of NMIBC finally need CT. Diagnosis at recurrence and combination of RC and CT tend to better survivals. Analyses that are more detailed are ongoing to evaluate clinical benefits according to the different clinical features.